Events

Russia’s next political cycle: who sets the rules of the game?

The elections to the Russian State Duma on September 17th-19th will not dramatically change Russia’s course of political and economic nationalism in recent years. The Kremlin remains a dominating political force and the principal decision-maker in Russia. However, this election opens a new period in the country’s political history leading up to the next major milestone – the 2024 presidential elections. Vladimir Putin has paved the way for himself to stay in power almost indefinitely, but will he choose to go down this path and what may prevent him from doing so?

On October 7th, Benjamin Wegg-Prosser, Managing Director, looked into the results of the parliamentary elections together with Alexander Smotrov, Practice Lead for CEE, Russia and Eurasia, Global Counsel; and the renowned Abbas Gallyamov, Russian political commentator; to understand who and how will set the political agenda in Russia in the coming years, what factors will drive this agenda and how Russia’s economic partners and investors might be impacted.

The discussion specifically focused on the following areas:

  • Who are the new faces in the Russian parliament – how and why do they matter? Will the United Russia remain united and influential in the next Duma?
     
  • What factors will drive the legislative agenda in the next political cycle? Are we expecting further shifts towards greater political control, Russia’s international self-isolation and search for new sources of budget revenues through redistribution of wealth?
     
  • What are the main scenarios for Russia in the next few years? How will the current system need to adapt to stay in power for longer? What could be the new “social contract” between the elite and the public?

Rare Diseases Forum 2024: Securing Europe's competitiveness in R&D for people living with rare diseases

Details:

Featuring keynotes and panel discussions with a focus on the EU's role in enhancing competitiveness in life sciences, fostering investment in the rare diseases sector, and examining the benefits of a competitive agenda for those with rare diseases. 

The event is convened by Global Counsel on behalf of the forum partners, EURORDIS, RaDiOrg, EFPIA, Eucope, EuropaBio, Pharma.be, UCB, Novo Nordisk, Sanofi & Takeda.

Register